These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24810451)

  • 1. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
    Yun S; Anwer F; Vincelette ND
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810451
    [No Abstract]   [Full Text] [Related]  

  • 2. Double-edged sword of the new cancer therapeutics.
    Force T
    Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
    Wang HC; Lee CS; Liu TC
    Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
    Rasheed W; Flaim B; Seymour JF
    Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
    Orlandi EM; Rocca B; Pazzano AS; Ghio S
    Leuk Res; 2012 Jan; 36(1):e4-6. PubMed ID: 21890201
    [No Abstract]   [Full Text] [Related]  

  • 6. Dasatinib in chronic myelogenous leukemia.
    Kathula SK
    N Engl J Med; 2006 Sep; 355(10):1062; author reply 1063-4. PubMed ID: 16957155
    [No Abstract]   [Full Text] [Related]  

  • 7. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
    Novitzky-Basso I; Craddock C
    Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
    [No Abstract]   [Full Text] [Related]  

  • 8. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
    Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
    Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
    [No Abstract]   [Full Text] [Related]  

  • 9. Reversible pre-capillary pulmonary hypertension due to dasatinib.
    Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
    Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary arterial hypertension in patients treated by dasatinib.
    Montani D; Bergot E; Günther S; Savale L; Bergeron A; Bourdin A; Bouvaist H; Canuet M; Pison C; Macro M; Poubeau P; Girerd B; Natali D; Guignabert C; Perros F; O'Callaghan DS; Jaïs X; Tubert-Bitter P; Zalcman G; Sitbon O; Simonneau G; Humbert M
    Circulation; 2012 May; 125(17):2128-37. PubMed ID: 22451584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].
    Ryczek R; Góra-Tybor J; Betkier-Lipińska K; Cwetsch A
    Pol Merkur Lekarski; 2013 Jun; 34(204):342-4. PubMed ID: 23882932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.
    Roux C; Nicolini FE; Rea D; Niault M; Mollica L; Berger F; Chassagne-Clément C; Tigaud I; Tulliez M; Giraudier S; Turhan A; Rousselot P; Legros L
    Blood; 2013 Oct; 122(17):3082-4. PubMed ID: 24159167
    [No Abstract]   [Full Text] [Related]  

  • 13. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
    Sano M; Saotome M; Urushida T; Katoh H; Satoh H; Ohnishi K; Hayashi H
    Intern Med; 2012; 51(17):2337-40. PubMed ID: 22975544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia.
    Ono Y; Mori T; Kato J; Yamane A; Yajima T; Iwao Y; Hibi T; Okamoto S
    Int J Hematol; 2010 Oct; 92(3):556-8. PubMed ID: 20824400
    [No Abstract]   [Full Text] [Related]  

  • 16. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
    Hennigs JK; Keller G; Baumann HJ; Honecker F; Kluge S; Bokemeyer C; Brümmendorf TH; Klose H
    BMC Pulm Med; 2011 May; 11():30. PubMed ID: 21605451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia.
    Samimi S; Chu E; Seykora J; Loren A; Vittorio C; Rook A; Rosenbach M; Kim EJ
    JAMA Dermatol; 2013 May; 149(5):637-9. PubMed ID: 23677113
    [No Abstract]   [Full Text] [Related]  

  • 18. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs: paliperidone, dasatinib, and decitabine.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(2):298-302. PubMed ID: 17510013
    [No Abstract]   [Full Text] [Related]  

  • 20. Dasatinib: pulmonary arterial hypertension. French data.
    Prescrire Int; 2011 Oct; 20(120):241. PubMed ID: 21970091
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.